La plèvre iatrogénique = Iatrogenic pleura diseaseCAMUS, P; LEBARGY, F; BONNIAUD, P et al.Revue des maladies respiratoires actualités (Print). 2013, Vol 5, Num 3, pp 136-139, issn 1877-1203, 4 p.Conference Paper

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell linesEUSTACE, Alex J; DOWLING, Paul; HENRY, Michael et al.Journal of proteomics (Print). 2011, Vol 74, Num 4, pp 490-501, issn 1874-3919, 12 p.Article

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib : Rationale for patient selectionFEI HUANG; REEVES, Karen; XIA HAN et al.Cancer research (Baltimore). 2007, Vol 67, Num 5, pp 2226-2238, issn 0008-5472, 13 p.Article

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptorBROWNLOW, N; MOL, C; HAYFORD, C et al.Leukemia. 2009, Vol 23, Num 3, pp 590-594, issn 0887-6924, 5 p.Article

Profound Inhibition of Antigen-SpecificT-Cell Effector Functions by DasatinibWEICHSEL, Ralf; DIX, Carolin; EINSELE, Hermann et al.Clinical cancer research. 2008, Vol 14, Num 8, pp 2484-2491, issn 1078-0432, 8 p.Article

Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collectionZHONGZHOU SHEN; PING KANG; RAHAVENDRAN, Sadayappan V et al.Journal of pharmaceutical and biomedical analysis. 2012, Vol 67-68, pp 92-97, issn 0731-7085, 6 p.Article

Dasatinib, imatinib and staurosporine capture compounds: Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS)FISCHER, Jenny J; DALHOFF, Christian; KOESTER, Hubert et al.Journal of proteomics (Print). 2011, Vol 75, Num 1, pp 160-168, issn 1874-3919, 9 p.Conference Paper

Dasatinib inhibits proinflammatory functions of mature human neutrophilsFUTOSI, Krisztina; NEMETH, Tamas; PICK, Robert et al.Blood. 2012, Vol 119, Num 21, pp 4981-4991, issn 0006-4971, 11 p.Article

CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitorsMAKISHIMA, H; SUGIMOTO, Y; SZPURKA, H et al.Leukemia. 2012, Vol 26, Num 7, pp 1547-1554, issn 0887-6924, 8 p.Article

Dasatinib enhances megakaryocyte differentiation but inhibits platelet formationMAZHARIAN, Alexandra; GHEVAERT, Cedric; LIN ZHANG et al.Blood. 2011, Vol 117, Num 19, pp 5198-5206, issn 0006-4971, 9 p.Article

Metabolism and Disposition of Dasatinib after Oral Administration to HumansCHRISTOPHER, Lisa J; DONGHUI CUI; GALBRAITH, Susan et al.Drug metabolism and disposition. 2008, Vol 36, Num 7, pp 1357-1364, issn 0090-9556, 8 p.Article

Glucocorticosteroids Rescue Basophils from Dasatinib-Augmented Immunoglobulin E-Mediated Histamine ReleaseHERRMANN, Harald; BLATT, Katharina; GHANIM, Viviane et al.International archives of allergy and immunology. 2012, Vol 159, Num 1, pp 15-22, issn 1018-2438, 8 p.Article

Nuclear EGFR contributes to acquired resistance to cetuximabLI, C; IIDA, M; DUNN, E. F et al.Oncogene (Basingstoke). 2009, Vol 28, Num 43, pp 3801-3813, issn 0950-9232, 13 p.Article

Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivativesJIN CAI; SHAONING ZHANG; MING ZHENG et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 2, pp 806-810, issn 0960-894X, 5 p.Article

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cellsREMSING RIX, L. L; RIX, U; TILL, J. H et al.Leukemia. 2009, Vol 23, Num 3, pp 477-485, issn 0887-6924, 9 p.Article

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL^TM), a multi-targeted kinase inhibitorFENG LUO; BARRETT, Yu Chen; GALBRAITH, Susan et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 6, pp 1065-1074, issn 0344-5704, 10 p.Article

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease featuresROSS, David M; BARTLEY, Paul A; GOYNE, Jarrad et al.Haematologica (Roma). 2011, Vol 96, Num 11, pp 1720-1722, issn 0390-6078, 3 p.Article

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemiaKIM, Dong-Wook; GOH, Yeow-Tee; BRADLEY-GARELIK, M. Brigid et al.International journal of hematology. 2009, Vol 89, Num 5, pp 664-672, issn 0925-5710, 9 p.Article

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemiaDONG HWAN KIM; KAMEL-REID, Suzanne; HONG CHANG et al.Haematologica (Roma). 2009, Vol 94, Num 1, pp 135-139, issn 0390-6078, 5 p.Article

Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and MetastasisCHAN, Christine M; XIA JING; PIKE, Laura A et al.Clinical cancer research (Print). 2012, Vol 18, Num 13, pp 3580-3591, issn 1078-0432, 12 p.Article

Lck is a key target of imatinib and dasatinib in T-cell activationLEE, K. C; OUWEHAND, I; GIANNINI, A. L et al.Leukemia. 2010, Vol 24, Num 4, pp 896-900, issn 0887-6924, 5 p.Article

Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid LeukemiasGUERROUAHEN, Bella S; FUTAMI, Muneyoshi; KORNBLAU, Steven M et al.Clinical cancer research (Print). 2010, Vol 16, Num 4, pp 1149-1158, issn 1078-0432, 10 p.Article

Enhanced Genetic Instability and Dasatinib Sensitivity in Mammary Tumor Cells Lacking NEDD9SINGH, Mahendra K; IZUMCHENKO, Eugene; KLEIN-SZANTO, Andres J et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 21, pp 8907-8916, issn 0008-5472, 10 p.Article

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemiaKUMAGAI, Takashi; MATSUKI, Eri; SHIRASUGI, Yukari et al.International journal of hematology. 2014, Vol 99, Num 1, pp 41-52, issn 0925-5710, 12 p.Article

Phase I trial of dasatinib and ixabepilone in patients with solid tumorsHERBOLSHEIMER, P; KAPOOR, R; SMITH, K. L et al.Investigational new drugs. 2013, Vol 31, Num 1, pp 92-98, issn 0167-6997, 7 p.Article